[Long-term hypotensive treatment by butofilolol].

Ann Cardiol Angeiol (Paris)

Published: June 1983

Eighteen patients, most of them plethoric, exhibiting stage I, II or III permanent essential hypertension, were treated following reduction of their weight excess with moderate doses of butofilolol. The minimum duration of treatment was 6 months; 5 patients received the drug for more than 1 year, and the last 3 for more than 18 months. An antihypertensive effect of butofilolol was observed in 11 of 18 cases. It was deemed very good or good in 9 patients, i.e. 50 p. cent; this is the usual rate of efficacy of beta-blocking agents in this indication. The effective dose, administered as 1 or 2 daily doses, is 200 mg/day on an average (range 75-300). No true manifestation of clinical or biological intolerance was recorded, although the patients were continued on low-calorie diets, and some of them showed disturbances of glycoregulation. It is the author's opinion that butofilolol constitute a good therapeutic approach to hypertension in plethoric subjects, when the weight reduction has failed to correct it adequately--if at all.

Download full-text PDF

Source

Publication Analysis

Top Keywords

[long-term hypotensive
4
hypotensive treatment
4
treatment butofilolol]
4
butofilolol] eighteen
4
patients
4
eighteen patients
4
patients plethoric
4
plethoric exhibiting
4
exhibiting stage
4
stage iii
4

Similar Publications

Valsartan (VST) is an angiotensin II receptor antagonist with low oral bioavailability. The present study developed a solid self-nanoemulsifying drug delivery system (S-SNEDDS) to enhance the oral absorption and bioavailability of VST. VST-loaded liquid SNEDDS (VST@L-SNEDDS) was prepared by investigating the solubility of VST and constructing the pseudo-ternary phase diagrams.

View Article and Find Full Text PDF

Background: Adrenomedullin (AM) is a potent angiogenic, antioxidant and anti-inflammatory peptide protecting the developing lung from injury due to bronchopulmonary dysplasia (BPD) of the preterm infant. At this stage, no data on the potential effects of chorioamnionitis (CA) occurrence and glucocorticoids (GC) administration on AM in developing lungs are still lacking.

Objective: to investigate, in a sheep-based model, the positive/side-effects of combined exposure to CA and GC on AM concentrations measured in bronchoalveolar lavage fluid (BALF).

View Article and Find Full Text PDF

Purpose Of Review: This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.

Recent Findings: CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern.

View Article and Find Full Text PDF

Disclosing long-term tolerance, efficacy and penetration properties of hyaluronic acid-coated latanoprost-loaded liposomes as chronic glaucoma therapy.

J Control Release

January 2025

Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, Universidad Complutense de Madrid (UCM), Madrid, Spain; Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, UCM; Health Research Institute (Instituto de Investigación Sanitaria) of the Hospital Clínico San Carlos (IdISSC), Madrid, Spain; University Institute of Industrial Pharmacy (IUFI), Faculty of Pharmacy, UCM, Madrid, Spain. Electronic address:

Frequent topical administration of hypotensive eye drops in glaucoma patients may lead to the development of dry eye disease (DED) symptoms, because of tear film destabilization and the adverse effects associated with antiglaucoma formulations. To address all this, in the current study preservative-free latanoprost-loaded (0.005 % w/v) synthetic phosphatidylcholine (1,2-dioleoyl-sn-glycero-3-phosphocholine 0.

View Article and Find Full Text PDF

Background: Limited data exist on the long-term impact of beta-blocker therapy after percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and preserved left ventricular ejection fraction (LVEF).

Objectives: The aim of the study was to evaluate the effects of early beta-blocker initiation vs no initiation following PCI in patients with stable CAD and preserved LVEF.

Methods: This retrospective cohort study employed target trial emulation and incident user design, utilizing the TriNetx database (2009-2024).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!